Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | BCL2 | P10415 | 3/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325047 | 0.83 | BCL2L1 (0.34) | BCL2BCL2L1SLC6A3 | |
| SCHEMBL30857548 | 0.83 | BCL2L1 (0.34) | BCL2BCL2L1SLC6A3 | |
| SCHEMBL22325249 | 0.78 | SLC6A3 (0.50) | BCL2SLC6A3 | |
| SCHEMBL30834660 | 0.74 | SLC6A3 (0.41) | SLC6A3 | |
| SCHEMBL30857697 | 0.74 | BCL2L1 (0.69) | BCL2BCL2L1 | |
| SCHEMBL22325101 | 0.72 | BCL2L1 (0.56) | BCL2BCL2L1 | |
| SCHEMBL30857610 | 0.72 | BCL2L1 (0.56) | BCL2BCL2L1 | |
| SCHEMBL19867784 | 0.72 | PTGS2 (0.50) | PTGS2PTGS1BCL2BCL2L1 | |
| SCHEMBL31759015 | 0.70 | BCL2L1 (0.48) | BCL2BCL2L1 | |
| SCHEMBL22335527 | 0.68 | SLC6A2 (0.40) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007685-A1 | ANTI-APOPTOTIC BCL-2 FAMILY PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BERRYBIO HONG KONG LTD (CN) | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007685-A1 | ANTI-APOPTOTIC BCL-2 FAMILY PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BCL2A1, BCL2, BCL2L1 | PTGS2 2636/4885PTGS1 2095/4885BCL2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.